Candriam S.C.A. Prelude Therapeutics Inc Transaction History

Candriam S.C.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	BUY	$4.61 - $8.5 $250,004 - $460,963	54,231 Added 43.17%	179,850 $1.09 Million
Q3 2022 Nov 10, 2022	BUY	$5.0 - $8.82 $628,095 - $1.11 Million	125,619 New	125,619 $830,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $34.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.